Liliana Ascione

584 posts

Liliana Ascione

@lilli_ash

Medical Oncologist 👩🏻‍⚕️ GU Oncology Research Fellow @DanaFarber University of Milan @LaStatale European Institute of Oncology @IEOufficiale

Boston Katılım Mayıs 2019

582 Takip Edilen298 Takipçiler

Liliana Ascione retweetledi

Emre Yekedüz@yekeduz_emre·2d

Pleased to share our study published in @CCR_AACR 👉 doi.org/10.1158/1078-0… 📍NF2 loss (merlin deficiency) in RCC delineates a distinctly aggressive biological phenotype: ⏫ heightened proliferative capacity, profound immune dysregulation, and recurrent alterations in cell cycle and DNA damage–response pathways. ⏬ limited efficacy of immunotherapy further underscores the pressing need for biomarker-driven, molecularly tailored therapeutic strategies. #Oncology #cancer #kidneycancer @DrChoueiri @MikeSerzanMD @WeiweiBian @OncoAlert @DanaFarberNews @DanaFarber_GU @AnkaraUni

English

2.8K

Liliana Ascione retweetledi

UroToday.com@urotoday·4d

Pre-cystectomy ctDNA burden may identify patients who can benefit from upfront radical cystectomy. Presentation by Rueben Ben David, MD. #EAU26 written coverage by @zklaassen_md > bit.ly/47MOGQm

English

Liliana Ascione retweetledi

Tom Powles@tompowles1·5d

Nectin-4 is expressed in almost all urothelial cancers . Nectin-4 fluorescence imaging during cystoscopy makes sense and seems to work well (see below) #EAU26 @urotoday . This potentially improves diagnostic accuracy. It would be good to generate large randomized data. @OncoAlert

English

202

16.1K

Liliana Ascione retweetledi

Julian Chavarriaga@chavarriagaj·6d

#EAU26 Dr. Fonteyne on MDT in oligometastatic prostate cancer: Evidence is growing, but context matters. 🔹 STOMP & ORIOLE: MDT → excellent local control, delays progression 🔹 RADIOSA: MDT + ADT > MDT alone for PFS 🔹 ARTO: MDT + SOC improved PFS and may signal OS benefit Yet major gaps remain: • Most data come from metachronous disease • Evidence in de novo oligometastatic HSPC is limited • Patient selection is key @uroweb @UroToday

English

101

6.3K

Liliana Ascione retweetledi

UroToday.com@urotoday·5d

Circulating and urine tumor DNA dynamics predict minimal residual disease and recurrence risk in locally advanced #UTUC: CURATE-UTUC – A multicenter prospective longitudinal cohort study. Presentation by Jiwei Huang. #EAU26 written coverage by @zklaassen_md > bit.ly/473DONU @Uroweb

English

731

Liliana Ascione retweetledi

Yüksel Ürün@DrYukselUrun·6d

Modern prostate cancer care is about intensity and timing. ADT + ARPI is the foundation. We then add radiation or chemo based on the individual. @APCCC_Lugano @Uroweb #EAU26

Julian Chavarriaga@chavarriagaj

#EAU26 @ChrisSweens1: the field is reaching a consensus in mHSPC. ADT + ARPI for nearly all patients, then personalize intensification: • SBRT for low-volume • Prostate RT in synchronous disease • Docetaxel if high-volume and chemofit 🕒 The hope for the future: biomarkers to guide therapy, global access, and drug prices coming down so evidence-based care becomes feasible worldwide. @uroweb @UroToday

English

11.5K

Liliana Ascione retweetledi

UroToday.com@urotoday·6d

PARPi in #mHSPC or should we wait until #mCRPC? Presentation by Gunhild von Amsberg, MD @MartiniKlinik. #EAU26 written coverage by @chavarriagaj @PSH_Urology > bit.ly/475dsv0 @Uroweb

English

1.8K

Liliana Ascione retweetledi

UroToday.com@urotoday·6d

Radiotherapy to primary tumor, What for? Presentation by @AlbertoBossial @GustaveRoussy. #EAU26 written coverage by @chavarriagaj @PSH_Urology > bit.ly/4bbehVx @Uroweb

English

1.1K

Liliana Ascione retweetledi

UroToday.com@urotoday·13 Mar

#EAU26 #Debate: Optimal management of oligorecurrent disease: Is there a role for lutetium PSMA? Presented by Wolfgang Fendler, MD @unidue. Written coverage by @zklaassen_md @GACancerCenter > bit.ly/46ZLGzV @Uroweb

English

633

Liliana Ascione retweetledi

UroToday.com@urotoday·6d

State-of-the-art lecture treatment de-intensification in #NMIBC. Presentation by @RobertoContieri @IstTumori. #EAU26 written coverage by @chavarriagaj @PSH_Urology > bit.ly/4sgk02k @Uroweb

English

Liliana Ascione retweetledi

Dr. Nina Niu Sanford@NiuSanford·6d

Someone suggested I make a table summarizing the video. Here it is!

Dr. Nina Niu Sanford@NiuSanford

Have you ever wondered whether you need to hold systemic during RT due to concern for additive toxicity? See this 10 min video. Categorized by systemic type (cytoxic chemo, IO, TKI, BRAF, etc) & RT regimen (SBRT/conventional/palliative) Slides🧵& full video below. 1/8

English

157

368

49.4K

Liliana Ascione retweetledi

UroToday.com@urotoday·13 Mar

#Debate Optimal management of oligorecurrent disease: Irradiate them! Presentation by @GiuliaMarvaso84 @IEOufficiale. #EAU26 written coverage by @zklaassen_md @GACancerCenter on UroToday > bit.ly/3P5U6zG @Uroweb

English

668

Liliana Ascione retweetledi

Zach Klaassen@zklaassen_md·13 Mar

#EAU26 Plenary Evidence from RCTs for MDT for oligorecurrent HSPC @urotoday

English

2.8K

Liliana Ascione retweetledi

UroToday.com@urotoday·6d

Debate beyond the muscle: Redefining #MIBC management: Pro: ctDNA should guide adjuvant decisions. Presentation by Jørgen Jensen, MD @AarhusUni. #EAU26 written coverage by @chavarriagaj @PSH_Urology > bit.ly/4lxPFd5 @Uroweb

English

1.4K

Liliana Ascione retweetledi

UroToday.com@urotoday·14 Mar

Extended vs limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk #ProstateCancer: 10 years of follow up - oncological outcomes from a randomized phase 3 trial. Presented by Matheus Ruggeri. #EAU26 written coverage by @zklaassen_md > bit.ly/40vh9q4 @Uroweb

English

10.8K

Liliana Ascione retweetledi

UroToday.com@urotoday·6d

State-of-the-Art Lecture bladder-sparing in #MIBC: The real-world evidence. Presented by @jteoh_hk @CUHKMedicine. #EAU26 written coverage by @chavarriagaj @PSH_Urology > bit.ly/4sFpuDr @Uroweb

English

2.7K

Liliana Ascione retweetledi

UroToday.com@urotoday·13 Mar

#EAU26 #Debate: Optimal management of de-novo oligometastatic disease: Can't say we always need PSMA PET/CT imaging in this setting! Presentation by @RenuEapen @PeterMacCC. Written coverage by @zklaassen_md @GACancerCenter > bit.ly/3P3zPLa @Uroweb

English

1.1K

Liliana Ascione retweetledi

Michael Hofman@DrMHofman·13 Mar

Proud moment and HUGE news from #EAU26: #PRIMARY2 shows PSMA PET/CT can safely halve prostate biopsies in men with equivocal MRI, avoiding biopsy in 49% without missing cancer. uroweb.org/news/scan-that…

English

248

19.1K

Liliana Ascione retweetledi

prof. Barbara Jereczek-Fossa@BarbaraJereczek·4 Şub

Joint effort of an amazing team, but @chadtang your commitment was vital💫

Chad Tang, MD@ChadTangMD

Extremely excited to share our latest article published @TheLancetOncol a few hours ago: authors.elsevier.com/a/1mYT65EIIgTS…. The WOLVERINE individual patient meta-analysis was an international collaboration and part of X-MET collaboration. Goal was to evaluate MDT in oligomet prostate ca.

English

378

Liliana Ascione retweetledi

prof. Barbara Jereczek-Fossa@BarbaraJereczek·14 Mar

Starting #EAU26 with the session on oligometastatic prostate cancer. Fantastic team session.

UroToday.com@urotoday

Who can really benefit from metastasis directed therapies? Presentation by @BarbaraJereczek. #EAU26 written coverage by @zklaassen_md > bit.ly/4sDy8Cr @Uroweb

English

Keşfet

@CCR_AACR @DrChoueiri @MikeSerzanMD @WeiweiBian @OncoAlert @DanaFarberNews @DanaFarber_GU @AnkaraUni